Su valor como predictor de diabetes de tipo 2
Importancia de la glucemia normal alta en ayunas en hombres jóvenes
Pueden predecir la aparición de diabetes de tipo 2 e indicar el inicio de intervenciones preventivas.
Autor/a: Dres. Amir Tirosh, Iris Shai, Dorit Tekes-Manova, Eran Israeli
Fuente: Diabetes in Young Men. N Engl J Med. 2005;353:1454-62.
Indice
1. Bibliografía
2. Desarrollo
2. Genuth S. Lowering the criterion for impaired fasting glucose is in order. Diabetes Care 2003;26:3331-2.
3. Borch-Johnsen K, Colagiuri S, Balkau B, et al. Creating a pandemic of prediabetes: the proposed new diagnostic criteria for impaired fasting glycaemia. Diabetologia 2004;47:1396-402.
4. Piche ME, Arcand-Bosse JF, Despres JP, Perusse L, Lemieux S, Weisnagel SJ. What is a normal glucose value? Differences in indexes of plasma glucose homeostasis in subjects with normal fasting glucose. Diabetes Care 004;27:2470-7.
5. Tai ES, Goh SY, Lee JJ, et al. Lowering the criterion for impaired fasting glucose: impact on disease prevalence and associated risk of diabetes and ischemic heart disease. Diabetes Care 2004;27:1728-34.
6. Schriger DL, Lorber B. Lowering the cut point for impaired fasting glucose: where is the evidence? Where is the logic? Diabetes Care 2004;27:592-601.
7. Bortheiry AL, Malerbi DA, Franco LJ. The ROC curve in the evaluation of fasting capillary blood glucose as a screening test for diabetes and IGT. Diabetes Care 1994; 17:1269-72.
8. Gabir MM, Hanson RL, Dabelea D, et al. The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care 2000;23: 1108-12.
9. Shaw JE, Zimmet PZ, Hodge AM, et al. Impaired fasting glucose: how low should it go? Diabetes Care 2000;23:34-9.
10. Bloomgarden ZT. Type 2 diabetes in the young: the evolving epidemic. Diabetes Care 2004;27:998-1010.
11. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet 2002;359:2072-7.
12. Idem. Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data. Diabetologia 2004;47:969-75.
13. Durbin RJ. Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Diabetes Obes Metab 2004;6:280-5.
14. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
15. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct Copyright © 2005 Massachusetts Medical Society. Diabetes Care 2004;27:155-61. [Erratum, Diabetes Care 2004;27:856.]
16. Unwin N, Shaw J, Zimmet P, Alberti KG. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 2002; 19:708-23.
17. American Diabetes Association. Screening for type 2 diabetes. Diabetes Care 2004; 27:Suppl 1:S11-S14.
18. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-97.
19. Rothman KJ, Greenland S. Modern epidemiology. 2nd ed. Philadelphia: Lippincott- Raven, 1998.
20. Juonala M, Viikari JS, Hutri-Kahonen N, et al. The 21-year follow-up of the Cardiovascular Risk in Young Finns Study: risk factor levels, secular trends and east-west difference. J Intern Med 2004;255:457-68.